-
Posted by
Two Blokes Jun 13 -
Filed in
Stock
-
4 views
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to include adults from 18 years of age.
